Remzi Onur Eren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Remzi Onur Eren has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Fasel
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
6 shared publications Catherine Ronet
Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland
4 shared publications- Mary-Anne Hartley
EPFL
4 shared publications Matteo Rossi
Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland
4 shared publicationsPatrik Castiglioni
Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland
4 shared publicationsChantal Desponds
Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland
3 shared publications
Latest Publications
- 13 May 2019
- Published by Springer Nature in Nature Cell Biology
- Vol. 21 (6) , 731-742
A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain
Deficiency in the deubiquitinating enzyme A20 causes severe inflammation in mice, and impaired A20 function is associated with human inflammatory diseases. A20 has been implicated in negatively regulating NF-κB signalling, cell death and inflammasome activation; however, the mechanisms by which A20 inhibits inflammation in vivo remain poorly understood. Genetic studies in mice revealed that its deubiquitinase activity is not essential for A20 anti-inflammatory function. Here we show that A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis and that this function depends on its zinc finger 7 (ZnF7). We provide genetic evidence that RIPK1 kinase-dependent, RIPK3–MLKL-mediated necroptosis drives inflammasome activation in A20-deficient macrophages and causes inflammatory arthritis in mice. Single-cell imaging revealed that RIPK3-dependent death caused inflammasome-dependent IL-1β release from lipopolysaccharide-stimulated A20-deficient macrophages. Importantly, mutation of the A20 ZnF7 ubiquitin binding domain caused arthritis in mice, arguing that ZnF7-dependent inhibition of necroptosis is critical for A20 anti-inflammatory function in vivo.
- 13 May 2019
- Published by Springer Nature in Nature Cell Biology
- Vol. 21 (6) , 731-742
A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain
Deficiency in the deubiquitinating enzyme A20 causes severe inflammation in mice, and impaired A20 function is associated with human inflammatory diseases. A20 has been implicated in negatively regulating NF-κB signalling, cell death and inflammasome activation; however, the mechanisms by which A20 inhibits inflammation in vivo remain poorly understood. Genetic studies in mice revealed that its deubiquitinase activity is not essential for A20 anti-inflammatory function. Here we show that A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis and that this function depends on its zinc finger 7 (ZnF7). We provide genetic evidence that RIPK1 kinase-dependent, RIPK3–MLKL-mediated necroptosis drives inflammasome activation in A20-deficient macrophages and causes inflammatory arthritis in mice. Single-cell imaging revealed that RIPK3-dependent death caused inflammasome-dependent IL-1β release from lipopolysaccharide-stimulated A20-deficient macrophages. Importantly, mutation of the A20 ZnF7 ubiquitin binding domain caused arthritis in mice, arguing that ZnF7-dependent inhibition of necroptosis is critical for A20 anti-inflammatory function in vivo.
- 24 April 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (19) , 4987-4992
Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis
Significance: Infection withLeishmania(Viannia) parasites can have different manifestations, ranging from localized cutaneous to disseminated and mucocutaneous leishmaniasis, that are prone to relapse after the healing. We previously described the association of the endosymbiontLeishmaniaRNA virus 1 (LRV1) with increased disease severity. Here, we showed that coinfection with the lymphocytic choriomeningitis virus (LCMV) or Toscana virus exacerbated the outcome ofLeishmania guyanensis-induced murine leishmaniasis, favoring parasite persistence and dissemination resulting in metastasis. Both endogenous and exogenous coinfections were dependent upon type I interferon responses. Strikingly, LCMV coinfection after the healing of leishmaniasis induced disease reactivation, overriding the protective adaptive immune response. Thus, viral infections may be a significant risk factor contributing to the pathological spectrum of human leishmaniasis.
- 24 April 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (19) , 4987-4992
Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis
Significance: Infection withLeishmania(Viannia) parasites can have different manifestations, ranging from localized cutaneous to disseminated and mucocutaneous leishmaniasis, that are prone to relapse after the healing. We previously described the association of the endosymbiontLeishmaniaRNA virus 1 (LRV1) with increased disease severity. Here, we showed that coinfection with the lymphocytic choriomeningitis virus (LCMV) or Toscana virus exacerbated the outcome ofLeishmania guyanensis-induced murine leishmaniasis, favoring parasite persistence and dissemination resulting in metastasis. Both endogenous and exogenous coinfections were dependent upon type I interferon responses. Strikingly, LCMV coinfection after the healing of leishmaniasis induced disease reactivation, overriding the protective adaptive immune response. Thus, viral infections may be a significant risk factor contributing to the pathological spectrum of human leishmaniasis.
- Open Access
- 18 January 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (1) , e0005240
Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid
Recent studies have shown that a cytoplasmic virus called Leishmaniavirus (LRV) is present in some Leishmania species and acts as a potent innate immunogen, aggravating lesional inflammation and development in mice. In humans, the presence of LRV in Leishmania guyanensis and in L. braziliensis was significantly correlated with poor treatment response and symptomatic relapse. So far, no clinical effort has used LRV for prophylactic purposes. In this context, we designed an original vaccine strategy that targeted LRV nested in Leishmania parasites to prevent virus-related complications. To this end, C57BL/6 mice were immunized with a recombinant LRV1 Leishmania guyanensis viral capsid polypeptide formulated with a T helper 1-polarizing adjuvant. LRV1-vaccinated mice had significant reduction in lesion size and parasite load when subsequently challenged with LRV1+ Leishmania guyanensis parasites. The protection conferred by this immunization could be reproduced in naïve mice via T-cell transfer from vaccinated mice but not by serum transfer. The induction of LRV1 specific T cells secreting IFN-γ was confirmed in vaccinated mice and provided strong evidence that LRV1-specific protection arose via a cell mediated immune response against the LRV1 capsid. Our studies suggest that immunization with LRV1 capsid could be of a preventive benefit in mitigating the elevated pathology associated with LRV1 bearing Leishmania infections and possibly avoiding symptomatic relapses after an initial treatment. This novel anti-endosymbiotic vaccine strategy could be exploited to control other infectious diseases, as similar viral infections are largely prevalent across pathogenic pathogens and could consequently open new vaccine opportunities. About 80% of leishmaniasis infections result in cutaneous manifestations with a broad symptomatic spectrum, ranging from self-healing localized to disseminated lesions. The mechanism behind these latter aggravated forms of leishmaniasis is still poorly understood. One possible factor is an endosymbiotic RNA virus identified in the cytoplasm of several Leishmania species (Leishmania RNA virus 1). LRV1 acts as a virulence factor, causing a destructive hyper-inflammatory response. In this study, we tested the prophylactic potential of a vaccine formulated with a recombinant LRV1 capsid and a T helper 1-polarizing adjuvant. Our approach conferred significant protection against LRV1+ Leishmania guyanensis infection, decreasing lesional inflammation and parasite burden. Further analysis demonstrated that this vaccine induced a potent T helper 1 response. Consequently, we propose that the LRV1-capsid is a promising vaccine component in order to reduce clinical complications (e.g. symptomatic relapses) in areas endemic to LRV1 co-infected Leishmania species. Taken together, we present an original strategy, whereby targeting the pervasive intracellular viruses within pathogens may reduce pathologic inflammation and offer an extra-genetic candidate that may circumvent escape mutations or poor response to drug treatment.
- 18 January 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (1) , e0005240
Open AccessExacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid
Recent studies have shown that a cytoplasmic virus called Leishmaniavirus (LRV) is present in some Leishmania species and acts as a potent innate immunogen, aggravating lesional inflammation and development in mice. In humans, the presence of LRV in Leishmania guyanensis and in L. braziliensis was significantly correlated with poor treatment response and symptomatic relapse. So far, no clinical effort has used LRV for prophylactic purposes. In this context, we designed an original vaccine strategy that targeted LRV nested in Leishmania parasites to prevent virus-related complications. To this end, C57BL/6 mice were immunized with a recombinant LRV1 Leishmania guyanensis viral capsid polypeptide formulated with a T helper 1-polarizing adjuvant. LRV1-vaccinated mice had significant reduction in lesion size and parasite load when subsequently challenged with LRV1+ Leishmania guyanensis parasites. The protection conferred by this immunization could be reproduced in naïve mice via T-cell transfer from vaccinated mice but not by serum transfer. The induction of LRV1 specific T cells secreting IFN-γ was confirmed in vaccinated mice and provided strong evidence that LRV1-specific protection arose via a cell mediated immune response against the LRV1 capsid. Our studies suggest that immunization with LRV1 capsid could be of a preventive benefit in mitigating the elevated pathology associated with LRV1 bearing Leishmania infections and possibly avoiding symptomatic relapses after an initial treatment. This novel anti-endosymbiotic vaccine strategy could be exploited to control other infectious diseases, as similar viral infections are largely prevalent across pathogenic pathogens and could consequently open new vaccine opportunities. About 80% of leishmaniasis infections result in cutaneous manifestations with a broad symptomatic spectrum, ranging from self-healing localized to disseminated lesions. The mechanism behind these latter aggravated forms of leishmaniasis is still poorly understood. One possible factor is an endosymbiotic RNA virus identified in the cytoplasm of several Leishmania species (Leishmania RNA virus 1). LRV1 acts as a virulence factor, causing a destructive hyper-inflammatory response. In this study, we tested the prophylactic potential of a vaccine formulated with a recombinant LRV1 capsid and a T helper 1-polarizing adjuvant. Our approach conferred significant protection against LRV1+ Leishmania guyanensis infection, decreasing lesional inflammation and parasite burden. Further analysis demonstrated that this vaccine induced a potent T helper 1 response. Consequently, we propose that the LRV1-capsid is a promising vaccine component in order to reduce clinical complications (e.g. symptomatic relapses) in areas endemic to LRV1 co-infected Leishmania species. Taken together, we present an original strategy, whereby targeting the pervasive intracellular viruses within pathogens may reduce pathologic inflammation and offer an extra-genetic candidate that may circumvent escape mutations or poor response to drug treatment.
- 1 January 2017
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 7 (16)
Macrophage Survival Assay Using High Content Microscopy
Macrophages maintain tissue homoeostasis by regulating inflammation and tissue repair mechanisms. Thus, the fate of macrophages has an impact on the state of the tissue. The aim of this protocol is to quantify macrophage survival using high content microscopy and image processing software. Here, we describe a high-content image based protocol to assess the effect of diverse stimuli in combination with pharmacological treatments on macrophage survival in a quantitative, unbiased and high-throughput manner. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.
- 1 January 2017
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 7 (16)
Macrophage Survival Assay Using High Content Microscopy
Macrophages maintain tissue homoeostasis by regulating inflammation and tissue repair mechanisms. Thus, the fate of macrophages has an impact on the state of the tissue. The aim of this protocol is to quantify macrophage survival using high content microscopy and image processing software. Here, we describe a high-content image based protocol to assess the effect of diverse stimuli in combination with pharmacological treatments on macrophage survival in a quantitative, unbiased and high-throughput manner. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.
- Open Access
- 22 September 2016
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 12 (9) , e1005852
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Cutaneous leishmaniasis has various outcomes, ranging from self-healing reddened papules to extensive open ulcerations that metastasise to secondary sites and are often resistant to standard therapies. In the case of L. guyanensis (L.g), about 5–10% of all infections result in metastatic complications. We recently showed that a cytoplasmic virus within L.g parasites (LRV1) is able to act as a potent innate immunogen, worsening disease outcome in a murine model. In this study, we investigated the immunophenotype of human patients infected by L.g and found a significant association between the inflammatory cytokine IL-17A, the presence of LRV1 and disease chronicity. Further, IL-17A was inversely correlated to the protective cytokine IFN-γ. These findings were experimentally corroborated in our murine model, where IL-17A produced in LRV1+ L.g infection contributed to parasite virulence and dissemination in the absence of IFN-γ. Additionally, IL-17A inhibition in mice using digoxin or SR1001, showed therapeutic promise in limiting parasite virulence. Thus, this murine model of LRV1-dependent infectious metastasis validated markers of disease chronicity in humans and elucidated the immunologic mechanism for the dissemination of Leishmania parasites to secondary sites. Moreover, it confirms the prognostic value of LRV1 and IL-17A detection to prevent metastatic leishmaniasis in human patients. Cutaneous leishmaniasis is a neglected parasitic disease particularly problematic in the South American tropics, where the parasites have an ability to migrate from the initial inoculation site in a process called “infectious metastasis”. Despite existing for centuries, the factors involved in parasite dissemination are largely unknown. We recently described that Leishmaniavirus (LRV), a virus present within some Leishmania parasites, is responsible for an exacerbation of the disease outcome in mice together with treatment failure and symptomatic relapse in human patients. In this paper we show that the expression of the pro-inflammatory cytokine IL-17A is correlated with disease chronicity in patients infected by LRV+ Leishmania parasites. We confirmed this finding in a unique murine model where IL-17A was also found to play a role in LRV1-dependent infectious metastasis. Additionally, using IL-17A as a prophylactic target, we were able to inhibit parasite proliferation and the development of infectious metastasis. Thus, we identify a pathogenic role for IL-17A in LRV1-dependent cutaneous leishmaniasis and infectious metastasis. More importantly, our data suggests that in addition to LRV presence, IL-17A is a marker of disease severity and could be a novel target to promote lesion resolution and prevent parasite dissemination.
- 22 September 2016
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 12 (9) , e1005852
Open AccessLeishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Cutaneous leishmaniasis has various outcomes, ranging from self-healing reddened papules to extensive open ulcerations that metastasise to secondary sites and are often resistant to standard therapies. In the case of L. guyanensis (L.g), about 5–10% of all infections result in metastatic complications. We recently showed that a cytoplasmic virus within L.g parasites (LRV1) is able to act as a potent innate immunogen, worsening disease outcome in a murine model. In this study, we investigated the immunophenotype of human patients infected by L.g and found a significant association between the inflammatory cytokine IL-17A, the presence of LRV1 and disease chronicity. Further, IL-17A was inversely correlated to the protective cytokine IFN-γ. These findings were experimentally corroborated in our murine model, where IL-17A produced in LRV1+ L.g infection contributed to parasite virulence and dissemination in the absence of IFN-γ. Additionally, IL-17A inhibition in mice using digoxin or SR1001, showed therapeutic promise in limiting parasite virulence. Thus, this murine model of LRV1-dependent infectious metastasis validated markers of disease chronicity in humans and elucidated the immunologic mechanism for the dissemination of Leishmania parasites to secondary sites. Moreover, it confirms the prognostic value of LRV1 and IL-17A detection to prevent metastatic leishmaniasis in human patients. Cutaneous leishmaniasis is a neglected parasitic disease particularly problematic in the South American tropics, where the parasites have an ability to migrate from the initial inoculation site in a process called “infectious metastasis”. Despite existing for centuries, the factors involved in parasite dissemination are largely unknown. We recently described that Leishmaniavirus (LRV), a virus present within some Leishmania parasites, is responsible for an exacerbation of the disease outcome in mice together with treatment failure and symptomatic relapse in human patients. In this paper we show that the expression of the pro-inflammatory cytokine IL-17A is correlated with disease chronicity in patients infected by LRV+ Leishmania parasites. We confirmed this finding in a unique murine model where IL-17A was also found to play a role in LRV1-dependent infectious metastasis. Additionally, using IL-17A as a prophylactic target, we were able to inhibit parasite proliferation and the development of infectious metastasis. Thus, we identify a pathogenic role for IL-17A in LRV1-dependent cutaneous leishmaniasis and infectious metastasis. More importantly, our data suggests that in addition to LRV presence, IL-17A is a marker of disease severity and could be a novel target to promote lesion resolution and prevent parasite dissemination.
- 1 September 2016
- Published by Elsevier in Cell Host & Microbe
- Vol. 20 (3) , 318-328
Mammalian Innate Immune Response to a Leishmania -Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence
- 1 September 2016
- Published by Elsevier in Cell Host & Microbe
- Vol. 20 (3) , 318-328
Mammalian Innate Immune Response to a Leishmania -Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence
- Open Access
- 18 April 2016
- Published by Springer Nature in Cell Death Discovery
- Vol. 2 (1) , 16024
Caspase-mediated cleavage of raptor participates in the inactivation of mTORC1 during cell death
The mammalian target of rapamycin complex 1 (mTORC1) is a highly conserved protein complex regulating key pathways in cell growth. Hyperactivation of mTORC1 is implicated in numerous cancers, thus making it a potential broad-spectrum chemotherapeutic target. Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand. All treatments induced cleavage in the mTORC1 component, raptor, resulting in decreased raptor–mTOR interaction and subsequent inhibition of the mTORC1-mediated phosphorylation of downstream substrates (S6K and 4E-BP1). The cleavage was primarily mediated by caspase-6 and occurred at two sites. Mutagenesis at one of these sites, conferred resistance to cell death, indicating that raptor cleavage is important in chemotherapeutic apoptosis.
- 18 April 2016
- Published by Springer Nature in Cell Death Discovery
- Vol. 2 (1) , 16024
Open AccessCaspase-mediated cleavage of raptor participates in the inactivation of mTORC1 during cell death
The mammalian target of rapamycin complex 1 (mTORC1) is a highly conserved protein complex regulating key pathways in cell growth. Hyperactivation of mTORC1 is implicated in numerous cancers, thus making it a potential broad-spectrum chemotherapeutic target. Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand. All treatments induced cleavage in the mTORC1 component, raptor, resulting in decreased raptor–mTOR interaction and subsequent inhibition of the mTORC1-mediated phosphorylation of downstream substrates (S6K and 4E-BP1). The cleavage was primarily mediated by caspase-6 and occurred at two sites. Mutagenesis at one of these sites, conferred resistance to cell death, indicating that raptor cleavage is important in chemotherapeutic apoptosis.
- Open Access
- 28 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e86844
Interferon-γ Induces Expression of MHC Class II on Intestinal Epithelial Cells and Protects Mice from Colitis
Immune responses against intestinal microbiota contribute to the pathogenesis of inflammatory bowel diseases (IBD) and involve CD4+ T cells, which are activated by major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells (APCs). However, it is largely unexplored how inflammation-induced MHCII expression by intestinal epithelial cells (IEC) affects CD4+ T cell-mediated immunity or tolerance induction in vivo. Here, we investigated how epithelial MHCII expression is induced and how a deficiency in inducible epithelial MHCII expression alters susceptibility to colitis and the outcome of colon-specific immune responses. Colitis was induced in mice that lacked inducible expression of MHCII molecules on all nonhematopoietic cells, or specifically on IECs, by continuous infection with Helicobacter hepaticus and administration of interleukin (IL)-10 receptor-blocking antibodies (anti-IL10R mAb). To assess the role of interferon (IFN)-γ in inducing epithelial MHCII expression, the T cell adoptive transfer model of colitis was used. Abrogation of MHCII expression by nonhematopoietic cells or IECs induces colitis associated with increased colonic frequencies of innate immune cells and expression of proinflammatory cytokines. CD4+ T-helper type (Th)1 cells - but not group 3 innate lymphoid cells (ILCs) or Th17 cells - are elevated, resulting in an unfavourably altered ratio between CD4+ T cells and forkhead box P3 (FoxP3)+ regulatory T (Treg) cells. IFN-γ produced mainly by CD4+ T cells is required to upregulate MHCII expression by IECs. These results suggest that, in addition to its proinflammatory roles, IFN-γ exerts a critical anti-inflammatory function in the intestine which protects against colitis by inducing MHCII expression on IECs. This may explain the failure of anti-IFN-γ treatment to induce remission in IBD patients, despite the association of elevated IFN-γ and IBD.
- 28 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e86844
Open AccessInterferon-γ Induces Expression of MHC Class II on Intestinal Epithelial Cells and Protects Mice from Colitis
Immune responses against intestinal microbiota contribute to the pathogenesis of inflammatory bowel diseases (IBD) and involve CD4+ T cells, which are activated by major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells (APCs). However, it is largely unexplored how inflammation-induced MHCII expression by intestinal epithelial cells (IEC) affects CD4+ T cell-mediated immunity or tolerance induction in vivo. Here, we investigated how epithelial MHCII expression is induced and how a deficiency in inducible epithelial MHCII expression alters susceptibility to colitis and the outcome of colon-specific immune responses. Colitis was induced in mice that lacked inducible expression of MHCII molecules on all nonhematopoietic cells, or specifically on IECs, by continuous infection with Helicobacter hepaticus and administration of interleukin (IL)-10 receptor-blocking antibodies (anti-IL10R mAb). To assess the role of interferon (IFN)-γ in inducing epithelial MHCII expression, the T cell adoptive transfer model of colitis was used. Abrogation of MHCII expression by nonhematopoietic cells or IECs induces colitis associated with increased colonic frequencies of innate immune cells and expression of proinflammatory cytokines. CD4+ T-helper type (Th)1 cells - but not group 3 innate lymphoid cells (ILCs) or Th17 cells - are elevated, resulting in an unfavourably altered ratio between CD4+ T cells and forkhead box P3 (FoxP3)+ regulatory T (Treg) cells. IFN-γ produced mainly by CD4+ T cells is required to upregulate MHCII expression by IECs. These results suggest that, in addition to its proinflammatory roles, IFN-γ exerts a critical anti-inflammatory function in the intestine which protects against colitis by inducing MHCII expression on IECs. This may explain the failure of anti-IFN-γ treatment to induce remission in IBD patients, despite the association of elevated IFN-γ and IBD.